This year’s agenda has been curated to provide you with the latest innovations, regulatory updates, and strategies on how industry and clinical experts are currently using adaptive designs in their clinical trials for successful drug, medical device and therapy development.
Giving you a fresh take on this vital area of biopharma, the event will ride the wave of technology within the pharmaceutical industry, as we consider how the increasing use of smartphone apps and digital devices is changing the way trials run. Simultaneously, the event will also explore how adaptive designs are being used for the production of personalised medicines and personalised therapies.
Featured Speakers include:
James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
Alex Sverdlov, Director, Statistical Scientist, Novartis
Frank Fleisher, Principal Methodology Statistician, Boehringer-Ingelheim
Christine Fletcher, Executive Director Biostatistics, Amgen
Chris Harbron, Principal Statistical Scientist, Roche
Olivier Collignon, Biostatistician, European Medicines Agency
Beatrice Panico, Medical Advisor, MHRA
Corine Baayen, Senior Biostatistician, H.Lundbeck
Key Highlights
Explore the current industry outlook and evaluate the promises and challenges of digital technology use
Hear exciting case studies on enrichment designs and group sequential trials
Discover how big pharma companies are using Platform Trials and self-adapting priors to advance their adaptive clinical trials
Examine the use of adaptive clinical trials are used to produce targeted therapies
Learn from the latest regulatory perspectives from MHRA and EMA, including planning and assessing umbrella and basket trials
Early Bird: Book by Dec 15 to save £400. Book by Jan 31 to save £200. Book by 28 Feb to save £100.
Giving you a fresh take on this vital area of biopharma, the event will ride the wave of technology within the pharmaceutical industry, as we consider how the increasing use of smartphone apps and digital devices is changing the way trials run. Simultaneously, the event will also explore how adaptive designs are being used for the production of personalised medicines and personalised therapies.
Featured Speakers include:
James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
Alex Sverdlov, Director, Statistical Scientist, Novartis
Frank Fleisher, Principal Methodology Statistician, Boehringer-Ingelheim
Christine Fletcher, Executive Director Biostatistics, Amgen
Chris Harbron, Principal Statistical Scientist, Roche
Olivier Collignon, Biostatistician, European Medicines Agency
Beatrice Panico, Medical Advisor, MHRA
Corine Baayen, Senior Biostatistician, H.Lundbeck
Key Highlights
Explore the current industry outlook and evaluate the promises and challenges of digital technology use
Hear exciting case studies on enrichment designs and group sequential trials
Discover how big pharma companies are using Platform Trials and self-adapting priors to advance their adaptive clinical trials
Examine the use of adaptive clinical trials are used to produce targeted therapies
Learn from the latest regulatory perspectives from MHRA and EMA, including planning and assessing umbrella and basket trials
Early Bird: Book by Dec 15 to save £400. Book by Jan 31 to save £200. Book by 28 Feb to save £100.
